definiumtx.comCrawled Nov 9, 2026
DT402 is the R-enatiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.
Definium’s clinical trials explore psychedelic medicine for anxiety, depression, and autism spectrum disorder.
Definium’s patient advocacy team collaborates with advocacy groups and patient communities to incorporate patient and caregiver input into drug development.
Definium integrates advances in neuroscience and clinical research with scientific and regulatory rigor to generate evidence-based data on psychedelic safety, efficacy, and mechanisms.
Definium’s newsroom provides journalists and media professionals with brand assets, fact sheets, logos, images, and downloadable resources.
Definium announced positive topline results from its Phase 3 study, Emerge, testing a pharmaceutically optimized LSD formulation for major depressive disorder.
Our team met in the nation's capital with lawmakers, clinical researchers and advocates to discuss the ongoing research in psychedelic medicines and what the future holds for these treatments.
The Definium newsroom offers fact sheets, media assets, and resources about the company’s mission to advance psychiatry.
Brandi Roberts brings 25+ years in life sciences finance. As CFO of Longboard Pharmaceuticals, she led its IPO and $2.6B acquisition by Lundbeck in 2024.
Dan joined as CMO in 2021 from HealthMode. Board certified in Psychiatry and Addiction Medicine, he led digital medicine strategy at Pfizer's Innovation Lab.
Meet Definium Therapeutics' leadership team—seasoned researchers and problem-solvers driving innovation in psychedelic medicine to forge a new era of psychiatry.
Chief Regulatory Officer Dr. Pratt has three decades in drug development, overseeing COBENFY FDA approval and holding leadership roles at Karuna and Lundbeck.
Definium Therapeutics offers contact information for media inquiries, investor relations, clinical trials, legal, medical affairs, and careers.
Definium Therapeutics is forging a new era in psychiatry by harnessing the full therapeutic potential of psychedelic medicine.
Definium Therapeutics describes how it collects, uses, and protects personal information in its privacy notice and data practices.
Definium Therapeutics ensures website accessibility for all users and outlines its standards and initiatives.
Definium’s expanded access program allows eligible patients to request investigational treatments outside clinical trials.
The page provides legal information, terms of use, and disclaimers for Definium Therapeutics’ website and investigational products.
